Authors
Latest:
Dr. Guarino on IMMU-132 in Advanced Metastatic Lung CancerMichael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-ΤROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.
Latest:
Dr. Hall on Multigene Target Panels for Genetic WeaknessesMichael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.
Latest:
Dr. Hall on the Importance of Genetic Testing in Pancreatic CancerMichael J. Hall, MD, MS, chair, Department of Clinical Genetics, director, Gastrointestinal Risk Assessment, associate professor, Fox Chase Cancer Center, discusses the importance of genetic testing in pancreatic cancer.
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced PatientsA mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Latest:
Dr. Mauro on the Risks of Disease Progression in MyelofibrosisMichael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.
Latest:
Dr. Morris on Logistical Challenges of Using 177Lu-PSMA-617 in Prostate CancerMichael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer.
Latest:
Dr Overman on Future Research Directions in GI CancerMichael J. Overman, MD, discusses future research directions in gastrointestinal cancers.
Latest:
Dr. Pishvaian on the Implications of the RATIONALE-306 Trial in ESCCMichael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.
Latest:
Dr. Thirman on the Rationale for Using SNDX-5613 in Acute LeukemiasMichael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.
Latest:
Dr. Gould on the Implications of the NELSON Trial in Lung CancerMichael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.
Latest:
It's Time to Take Action on Quality MeasuresQuality improvement is a method for ensuring that all the activities necessary to design, develop, and implement a product or service are effective and efficient with respect to the system and its performance.
Latest:
Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or SarcomaArta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.
Latest:
The Oncology Care Model: Roadmap or Distraction for Commercial Payers?It's clear that Medicare needs a proactive cancer strategy, hence the launch of the Oncology Care Model.
Latest:
Dr. Michael Krauthammer on NF1 Mutations in MelanomaMichael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.
Latest:
Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCCMichael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).
Latest:
Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.
Latest:
Dr. Krychman on Treating Cancer-Related Sexual IssuesMichael L. Krychman, MD, Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine, discusses managing and treating sexual health concerns in cancer patients and survivors.
Latest:
Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell TherapyBijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.
Latest:
Dr. Michael Lim on Toxicities of Checkpoint InhibitorsMichael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.
Latest:
Dr. Link on Evolution of Treatment in Pediatric CancerMichael Link, MD, professor of pediatrics, Stanford Cancer Institute, 2018 Giant of Cancer Care in Pediatrics, discusses the evolution of treatment in pediatric cancer.
Latest:
Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular CarcinomaMichael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.
Latest:
On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone TherapiesA new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.
Latest:
Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating AgentsErythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase
Latest:
Dr. Mauro on the Risks of Disease Progression in MyelofibrosisMichael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.
